GO:0004115 3',5'-cyclic-AMP phosphodiesterase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004115 describes the catalytic hydrolysis of 3',5'-cyclic AMP (cAMP) to AMP and H+, a reaction that terminates cAMP signalling.
• The activity is carried out by cyclic nucleotide phosphodiesterases (PDEs), a superfamily of enzymes that includes cAMP-specific and dual-specificity isoforms.
• Calcium and potassium ions modulate basal phosphodiesterase activity, linking cAMP breakdown to cellular ion homeostasis.
• Endogenous phosphodiesterase activators can be regulated transsynaptically, providing a mechanism for activity-dependent control of cAMP levels.
• Phosphodiesterase activity is induced during differentiation in model organisms such as Dictyostelium discoideum, demonstrating developmental regulation.
• Altered phosphodiesterase activity has been observed in human disease, including phaeochromocytoma, and is a target for therapeutic intervention in cardiac remodelling.
Description
3',5'-cyclic-AMP phosphodiesterase activity (GO:0004115) is a molecular function that catalyses the hydrolysis of 3',5'-cyclic AMP (cAMP) to AMP and a proton. This reaction is essential for terminating cAMP signalling, a ubiquitous second messenger that controls diverse cellular processes including metabolism, gene expression, and cell proliferation. By degrading cAMP, phosphodiesterases (PDEs) shape the amplitude and duration of cAMP signals, making them critical regulators of signal transduction. Researchers study this activity to understand how cells decode cAMP signals and to develop therapeutics that modulate cAMP pathways in diseases such as cancer, cardiovascular disorders, and neurological conditions. The enzyme activity is conserved across evolution, from parasitic flatworms to mammals, underscoring its fundamental biological importance.
3',5'-cyclic-AMP phosphodiesterase activity At A Glance
| GO ID | GO:0004115 |
|---|---|
| GO term | 3',5'-cyclic-AMP phosphodiesterase activity |
| Ontology | molecular_function |
| Synonym | cAMP-specific phosphodiesterase activity; 3',5'-cAMP-specific phosphodiesterase activity; adenosine 3',5'-cyclophosphate-specific phosphodiesterase activity |
| Major function | Hydrolysis of cAMP to AMP and H+, terminating cAMP signalling |
| Reaction | 3',5'-cyclic AMP + H2O = AMP + H+ |
| Cofactors | Calcium ions can modulate activity; potassium ions inhibit basal activity |
| Regulation | Regulated by endogenous activators and transsynaptic signals |
| Disease relevance | Phaeochromocytoma, cardiac remodelling, and other cAMP-related disorders |
What Is GO:0004115?
According to the Gene Ontology, GO:0004115 is defined as the catalysis of the reaction: 3',5'-cyclic AMP + H2O = AMP + H+. In other words, it is the enzymatic activity that breaks down cAMP into AMP and a hydrogen ion. This activity is synonymous with cAMP-specific phosphodiesterase activity and is a key mechanism for attenuating cAMP-mediated signalling.
Why Is 3',5'-cyclic-AMP phosphodiesterase activity Important in Cell Biology?
3',5'-cyclic-AMP phosphodiesterase activity is fundamental to cellular signalling because it controls the intracellular levels of cAMP, a second messenger involved in numerous physiological processes. Dysregulation of this activity can lead to aberrant cAMP signalling, which is implicated in diseases such as cancer, heart failure, and neurological disorders. Understanding the mechanisms and regulation of this activity is therefore crucial for developing targeted therapies that modulate cAMP pathways.
• Terminates cAMP signalling, preventing sustained activation of downstream effectors.
• Regulates cellular responses to hormones and neurotransmitters.
• Modulates cardiac contractility and remodelling; PDE9A inhibition attenuates cardiac remodelling.
• Involved in immune cell signalling, including T cell receptor regulation of PDE-2 and PDE-4.
• Plays a role in developmental processes, as shown by induction during Dictyostelium differentiation.
• Associated with phaeochromocytoma, where high serum activity has been reported.
• Target for anti-inflammatory and anti-cancer drugs.
• Influenced by ion concentrations, linking cAMP breakdown to cellular ion homeostasis.
• Regulated by endogenous activators that respond to synaptic activity.
• Conserved across species, from parasites to humans, indicating fundamental biological importance.
What Happens During 3',5'-cyclic-AMP phosphodiesterase activity?
Substrate recognition and binding
In simple terms: The enzyme grabs cAMP and holds it in place for cleavage.
Phosphodiesterases specifically bind 3',5'-cyclic AMP through conserved active-site residues. The binding is selective for cAMP over other cyclic nucleotides, ensuring specificity. This step is essential for the subsequent hydrolysis reaction.
Catalytic hydrolysis
In simple terms: Water is used to split cAMP into AMP and a proton.
The enzyme catalyses the hydrolysis of the cyclic phosphate bond in cAMP, yielding AMP and H+. This reaction is dependent on divalent cations such as calcium, which can modulate activity. The hydrolysis effectively terminates the cAMP signal.
Product release and signal termination
In simple terms: The products are released, and the cAMP signal is switched off.
After cleavage, AMP and H+ are released from the active site. The reduction in cAMP levels leads to decreased activation of downstream effectors such as protein kinase A, thereby terminating the signal.
Regulation by endogenous activators
In simple terms: Other proteins can turn the enzyme on or off.
Endogenous phosphodiesterase activators can enhance the enzyme's activity in response to transsynaptic signals, providing a dynamic way to regulate cAMP levels. This regulation is critical for synaptic plasticity and other activity-dependent processes.
Induction during differentiation
In simple terms: The enzyme can be newly made when cells differentiate.
In Dictyostelium discoideum, cAMP induces phosphodiesterase expression during amoeba differentiation, illustrating developmental control of this activity. This induction helps shape cAMP gradients that guide cell migration and differentiation.
Key Genes Involved in GO:0004115 3',5'-cyclic-AMP phosphodiesterase activity
The following genes encode phosphodiesterases or related proteins that carry out or regulate 3',5'-cyclic-AMP phosphodiesterase activity.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDE1 | Calcium/calmodulin-dependent phosphodiesterase | Regulates cAMP and cGMP; implicated in neuronal signalling |
| PDE2 | cGMP-stimulated phosphodiesterase | Regulated by T cell receptor ligation; immune function |
| PDE3 | cGMP-inhibited phosphodiesterase | Cardiac contractility and metabolism |
| PDE4 | cAMP-specific phosphodiesterase | Inflammation, memory, and T cell regulation |
| PDE5 | cGMP-specific phosphodiesterase | Smooth muscle relaxation; also affects cAMP |
| PDE7 | cAMP-specific phosphodiesterase | T cell activation and immune responses |
| PDE8 | cAMP-specific phosphodiesterase | Hormone secretion and cell growth |
| PDE9A | cGMP-specific phosphodiesterase | Cardiac remodelling; target of hederagenin |
| PDE10 | Dual-specificity phosphodiesterase | Neurodegeneration and schizophrenia |
| PDE11 | Dual-specificity phosphodiesterase | Sperm function and mood disorders |
| CALM1 | Calmodulin, calcium sensor | Activates PDE1 in response to calcium |
| PRKACA | cAMP-dependent protein kinase A | Downstream effector of cAMP signalling |
| GNAS | G protein alpha subunit | Activates adenylyl cyclase to produce cAMP |
| ADCY1 | Adenylyl cyclase | Synthesizes cAMP, opposing phosphodiesterase |
| PDE6 | Photoreceptor phosphodiesterase | Visual signal transduction |
| PDE12 | 3' phosphodiesterase | RNA processing; not cAMP-specific |
| ENPP1 | Ectonucleotide pyrophosphatase | Produces AMP, indirectly linked to cAMP |
How Is 3',5'-cyclic-AMP phosphodiesterase activity Regulated?
3',5'-cyclic-AMP phosphodiesterase activity is regulated at multiple levels. Calcium ions modulate basal activity, and physiological potassium concentrations can inhibit the enzyme. Endogenous activators respond to transsynaptic signals to increase phosphodiesterase activity, providing activity-dependent control. In differentiating Dictyostelium amoebae, cAMP induces phosphodiesterase expression, linking the activity to developmental programs. Additionally, T cell antigen receptor ligation rapidly regulates PDE-2 and PDE-4 activity, demonstrating acute regulation in immune cells.
3',5'-cyclic-AMP phosphodiesterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDE9A | Cardiac remodelling | PDE9A knockout mouse; hederagenin treatment |
| PDE4 | Inflammation, autoimmune disease | PDE4 knockout or inhibitor-treated T cells |
| PDE2 | T cell signalling | PDE2 knockout mice; thymocyte cultures |
| PDE1 | Neurodegeneration | PDE1 knockout neurons; calcium modulation |
| PDE3 | Heart failure | PDE3 knockout cardiomyocytes |
Phaeochromocytoma
High activity of cyclic 3',5'-nucleotide phosphodiesterase has been reported in sera of patients with phaeochromocytoma, suggesting a potential role as a biomarker or in disease pathology.
Cardiac remodelling
Hederagenin attenuates cardiac remodelling by targeting phosphodiesterase 9A, indicating that PDE9A inhibition may be a therapeutic strategy for heart failure.
Immune disorders
Rapid regulation of PDE-2 and PDE-4 following T cell receptor ligation highlights the importance of phosphodiesterase activity in immune responses and potential autoimmune conditions.
From 3',5'-cyclic-AMP phosphodiesterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PDE9A affect cardiac remodelling? | PDE9A knockout mouse |
| How does PDE4 regulate T cell activation? | PDE4 knockout or point-mutant T cells |
| What is the role of calcium in PDE1 activity? | PDE1 point mutations in calcium-binding domain |
| Can PDE2 overexpression alter cAMP levels? | PDE2 overexpression in cell lines |
| How does cAMP induction regulate PDE expression? | Dictyostelium discoideum differentiation model |
| Is PDE activity altered in phaeochromocytoma? | Patient serum samples and cell models |
How to Study the 3',5'-cyclic-AMP phosphodiesterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioenzymatic assay | Conversion of cAMP to AMP | Measuring PDE activity in serum or tissue |
| Fluorescence polarization | cAMP hydrolysis | High-throughput screening of inhibitors |
| Western blot | Protein expression levels | Detecting PDE isoforms in cell lysates |
| qRT-PCR | mRNA expression | Assessing induction of PDE genes |
| CRISPR knockout | Gene function | Studying loss-of-function phenotypes |
| Overexpression | Gain-of-function | Examining effects of increased PDE activity |
| Inhibitor treatment | Enzyme inhibition | Differentiating PDE isoforms |
Enzyme activity assays
Phosphodiesterase activity is typically measured using radiolabeled cAMP or fluorescent substrates, quantifying the conversion to AMP. Such assays have been used to characterize activity in sera and tissue extracts.
Inhibitor profiling
Selective inhibitors such as EHNA and rolipram are used to distinguish between PDE isoforms, as demonstrated in T cell studies.
Genetic manipulation
Knockout and overexpression models in cell lines and organisms help dissect the specific roles of phosphodiesterase genes.
Biochemical fractionation
Subcellular fractionation and Western blotting can localize phosphodiesterases and assess their regulation by ions or activators.
How CRISPR Can Be Used to Study GO:0004115 3',5'-cyclic-AMP phosphodiesterase activity
Knockout
CRISPR knockout of phosphodiesterase genes, such as PDE9A, can reveal their roles in cardiac remodelling and other processes. Knockout models help determine whether a specific PDE is required for cAMP homeostasis.
Point Mutation
Introducing point mutations in catalytic residues or regulatory domains can dissect the mechanism of phosphodiesterase activity, including calcium dependence.
Knock-in
Knock-in of tagged phosphodiesterases allows tracking of protein localization and interactions in live cells, facilitating studies of cAMP signalling dynamics.
Overexpression
Overexpression of phosphodiesterases can reduce cellular cAMP levels and phenocopy inhibition of cAMP pathways, useful for validating targets.
How EDITGENE Supports 3',5'-cyclic-AMP phosphodiesterase activity Research
Researchers studying 3',5'-cyclic-AMP phosphodiesterase activity-related genes often need to determine whether a candidate gene is causally involved in cAMP regulation, disease progression, or drug response. EDITGENE provides comprehensive CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for 3',5'-cyclic-AMP phosphodiesterase activity research.
Frequently Asked Questions About 3',5'-cyclic-AMP phosphodiesterase activity
What is 3',5'-cyclic-AMP phosphodiesterase activity?
It is the enzymatic activity that hydrolyzes cAMP to AMP and H+, encoded by GO:0004115.
What genes are involved in 3',5'-cyclic-AMP phosphodiesterase activity?
Genes include PDE1, PDE2, PDE3, PDE4, PDE5, PDE7, PDE8, PDE9A, PDE10, and PDE11, among others.
How is cAMP phosphodiesterase activity regulated?
It is regulated by calcium, potassium ions, endogenous activators, and transsynaptic signals.
What diseases are associated with phosphodiesterase activity?
Phaeochromocytoma, cardiac remodelling, and immune disorders have been linked to altered activity.
What is the reaction catalysed by GO:0004115?
3',5'-cyclic AMP + H2O = AMP + H+.
Which inhibitors target cAMP phosphodiesterases?
EHNA and rolipram are selective inhibitors used to study PDE2 and PDE4.
How can I measure phosphodiesterase activity?
Radioenzymatic assays, fluorescence polarization, and inhibitor profiling are common methods.
Is phosphodiesterase activity conserved across species?
Yes, it is found from parasites to humans, indicating fundamental importance.
What is the role of PDE9A in cardiac remodelling?
PDE9A inhibition by hederagenin attenuates cardiac remodelling, suggesting a therapeutic target.
How does cAMP induce phosphodiesterase expression?
In Dictyostelium discoideum, cAMP induces phosphodiesterase during differentiation.
Conclusion
3',5'-cyclic-AMP phosphodiesterase activity (GO:0004115) is a central molecular function that controls cAMP signalling by hydrolyzing cAMP to AMP. Its regulation by ions, activators, and developmental cues highlights its importance in physiology and disease. Understanding this activity through CRISPR models and biochemical assays can reveal new therapeutic opportunities for cancer, cardiac, and immune disorders.
References
- 1. Nakai A et al.. 1986. High activity of cyclic 3',5'-nucleotide phosphodiesterase in sera of patient with phaeochromocytoma.. Clin Endocrinol (Oxf) 24(4):409-14 PMID: 3017609
- 2. Davis CW et al.. 1978. Calcium-dependent 3':5'-cyclic nucleotide phosphodiesterase. Inhibition of basal activity at physiological levels of potassium ions.. J Biol Chem 253(24):8683-6 PMID: 214428
- 3. Walter RD. 1976. Properties of 3',5'-cyclic-AMP phosphodiesterase from Paragonimus africanus metacercariae.. Tropenmed Parasitol 27(3):337-42 PMID: 10655
- 4. Michie AM et al.. 1996. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.. Cell Signal 8(2):97-110 PMID: 8730511
- 5. Chen L et al.. 2026. Hederagenin Attenuates Cardiac Remodeling by Targeting Phosphodiesterase 9A.. Phytother Res 40(5):2710-2729 PMID: 41749398
- 6. Gnegy ME et al.. 1976. Regulation of transsynaptically elicited increase of 3':5'-cyclic AMP by endogenous phosphodiesterase activator.. Proc Natl Acad Sci U S A 73(2):352-5 PMID: 174103
- 8. Klein C. 1975. Induction of phosphodiesterase by cyclic adenosine 3':5'-monophosphate in differentiating Dictyostelium discoideum amoebae.. J Biol Chem 250(18):7134-8 PMID: 170256
